# A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

> **NCT05080842** · PHASE1 · TERMINATED · sponsor: **Accutar Biotechnology Inc** · enrollment: 21 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** AC682

## Key facts

- **NCT ID:** NCT05080842
- **Lead sponsor:** Accutar Biotechnology Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-11-12
- **Primary completion:** 2024-04-04
- **Final completion:** 2024-04-04
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Voluntarily terminate the study since the sponsor's development strategy was adjusted.
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05080842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05080842, "A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05080842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*